Articles by Blood Cancer Talks
KarMMa-3 trial evaluated ide-cel in MM, while the CARTITUDE-4 trial evaluated cilta-cel in MM.
Dr. Tefferi discussed choosing the right mentors, balancing the clinical and the research, and becoming a "master physician."
Dr. Dispenzieri, of the Mayo Clinic, joins the "Blood Cancer Talks" hosts to discuss how to treat and manage AL amyloidosis.
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
Shernan Holtan, MD, and the hosts discuss recent data on graft versus host disease prophylaxis.
Dr. Derman and the hosts discuss myeloma abstracts from ASH 2023, including the PERSEUS trial and the KarMMa-3 trial.
Dr. Dickinson joins "Blood Cancer Talks" hosts to discuss phase I and II trials on DLBCL, follicular lymphoma, and more.
Alexander Perl, MD, joins the hosts to discuss the management of newly diagnosed and relapsed FLT3-positive AML.
The episode also discusses Dr. Raza's book, "The First Cell," which recounts stories of her patients with terminal cancer.
Kate Cwynarski, MBBS, PhD, of the University of College London, discusses the management of CNS lymphomas.
This episode of "Blood Cancer Talks" discusses the biology and management of multiple myeloma and the role of venetoclax.
The episode also highlights the S1211 study, which is the first randomized controlled trial with high-risk enrichment in MM.
Dr. Horwitz and the hosts focus on the three most common types of PTCL and the latest research.
Uma Borate, MBBS, joins the hosts to discuss CCUS and the latest data.
Dr. Bartlett and the hosts explore the history of first-line treatments for patients with Hodgkin lymphoma.
Dr. Jain discusses how he addresses the acute toxicities that can arise after CAR T-cell therapy.
The hosts discuss the latest data on CAR-T from the summer conference season.
Dr. Sekeres also speaks about his time on the FDA ODAC and his latest book, titled "Drugs and the FDA."
Dr. Chari and the hosts also discuss a phase I trial of fixed-duration cevostamab, as well as a phase I trial of ABBV-383.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.